RESUMO
BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial. METHODS: ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m2 by body surface area) on day 1 of every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m2 by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 3). The maximum number of cycles of chemotherapy permitted was six. Randomisation was done with a minimisation method, and patients were stratified according to GCIG group, disease stage, and timing and outcome of cytoreductive surgery. Patients and clinicians were not masked to group allocation. The scheduling of surgery and use of neoadjuvant chemotherapy were determined by local multidisciplinary case review. In this post-hoc exploratory analysis of ICON8, progression-free survival was analysed using the landmark method and defined as the time interval between the date of pre-surgical planning radiological tumour assessment to the date of investigator-assessed clinical or radiological progression or death, whichever occurred first. This definition is different from the intention-to-treat primary progression-free survival analysis of ICON8, which defined progression-free survival as the time from randomisation to the date of first clinical or radiological progression or death, whichever occurred first. We also compared the extent of surgical cytoreduction with RECIST and GCIG CA125 responses. This post-hoc exploratory analysis includes only women recruited to ICON8 who were planned for neoadjuvant chemotherapy followed by DPS and had RECIST and/or GCIG CA125-evaluable disease. ICON8 is closed for enrolment and follow-up, and registered with ClinicalTrials.gov, NCT01654146. FINDINGS: Between June 6, 2011, and Nov 28, 2014, 1566 women were enrolled in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS. Median follow-up was 29·5 months (IQR 15·6-54·3) for the neoadjuvant chemotherapy followed by DPS population. Of 564 women who had RECIST-evaluable disease at trial entry, 348 (62%) had a complete or partial response. Of 727 women who were evaluable by GCIG CA125 criteria at the time of diagnosis, 610 (84%) had a CA125 response. Median progression-free survival was 14·4 months (95% CI 9·2-28·0; 297 events) for patients with a RECIST complete or partial response and 13·3 months (8·1-20·1; 171 events) for those with RECIST stable disease. Median progression-free survival for women with a GCIG CA125 response was 13·8 months (95% CI 8·8-23·4; 544 events) and 9·7 months (5·8-14·5; 111 events) for those without a GCIG CA125 response. Complete cytoreduction (R0) was achieved in 187 (56%) of 335 women with a RECIST complete or partial response and 73 (42%) of 172 women with RECIST stable disease. Complete cytoreduction was achieved in 290 (50%) of 576 women with a GCIG CA125 response and 30 (30%) of 101 women without a GCIG CA125 response. INTERPRETATION: The RECIST-defined radiological response rate was lower than that frequently quoted to patients in the clinic. RECIST and GCIG CA125 responses to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as individual predictive markers to stratify patients who are likely to benefit from DPS, but instead used in conjunction with the patient's clinical capacity to undergo cytoreductive surgery. A patient should not be denied surgery based solely on the lack of a RECIST or GCIG CA125 response. FUNDING: Cancer Research UK, UK Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia.
Assuntos
Carboplatina/administração & dosagem , Neoplasias das Tubas Uterinas/tratamento farmacológico , Neoplasias Ovarianas/tratamento farmacológico , Paclitaxel/administração & dosagem , Neoplasias Peritoneais/tratamento farmacológico , Idoso , Austrália , Antígeno Ca-125 , Carboplatina/efeitos adversos , Intervalo Livre de Doença , Neoplasias das Tubas Uterinas/genética , Neoplasias das Tubas Uterinas/patologia , Tubas Uterinas/patologia , Feminino , Humanos , Irlanda , Proteínas de Membrana , Pessoa de Meia-Idade , Terapia Neoadjuvante/efeitos adversos , Nova Zelândia , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , Paclitaxel/efeitos adversos , Neoplasias Peritoneais/genética , Neoplasias Peritoneais/patologia , Critérios de Avaliação de Resposta em Tumores SólidosRESUMO
BACKGROUND: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group. METHODS: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs). RESULTS: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006). CONCLUSIONS: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.
Assuntos
Neoplasias do Ânus/terapia , Carcinoma de Células Escamosas/terapia , Linfócitos do Interstício Tumoral/imunologia , Proteínas de Neoplasias/metabolismo , Infecções por Papillomavirus/terapia , Neoplasias do Ânus/imunologia , Neoplasias do Ânus/metabolismo , Neoplasias do Ânus/virologia , Carcinoma de Células Escamosas/imunologia , Carcinoma de Células Escamosas/metabolismo , Quimiorradioterapia , Estudos de Coortes , Inibidor p16 de Quinase Dependente de Ciclina , Intervalo Livre de Doença , Feminino , Humanos , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Masculino , Infecções por Papillomavirus/imunologia , Infecções por Papillomavirus/metabolismo , Prognóstico , Resultado do TratamentoRESUMO
On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin(R); Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-alpha2a for the treatment of patients with metastatic renal cell carcinoma. The approval was primarily based on results from a randomized, double-blind, placebo-controlled clinical trial. The primary efficacy endpoint, progression-free survival (PFS), was assessed by investigators and by an independent review committee (IRC) blinded to treatment assignment. In total, 649 patients (bevacizumab plus IFN, 327; placebo plus IFN, 322) were enrolled. The median PFS times, by investigator determination, were 10.2 months for the bevacizumab plus IFN arm and 5.4 months for the placebo plus IFN arm (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.49-0.72; p < .0001). The IRC analysis of 569 patients with available radiographs yielded similar results (median PFS time, 10.4 months versus 5.5 months; HR, 0.57; 95% CI, 0.45-0.72; p < .0001). There was no survival advantage (HR, 0.86; 95% CI, 0.72-1.04; p = .13). Support for the above results was provided by summarized results of a North American cooperative group study of bevacizumab plus IFN-alpha2b versus IFN-alpha2b alone. The median PFS times were 8.4 months versus 4.9 months in favor of the bevacizumab combination. There was no survival advantage. In the reviewed trial, serious adverse events and National Cancer Institute Common Terminology Criteria for Adverse Events grade >/=3 adverse events were reported more frequently in bevacizumab-treated patients (31% versus 19% and 63% versus 47%, respectively). The most common bevacizumab-related toxicities were bleeding/hemorrhage, hypertension, proteinuria, and venous or arterial thromboembolic events.
Assuntos
Inibidores da Angiogênese/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Interferon-alfa/administração & dosagem , Neoplasias Renais/tratamento farmacológico , Adulto , Anticorpos Monoclonais Humanizados , Bevacizumab , Carcinoma de Células Renais/mortalidade , Carcinoma de Células Renais/patologia , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Determinação de Ponto Final , Cloridrato de Erlotinib , Feminino , Humanos , Interferon alfa-2 , Neoplasias Renais/mortalidade , Neoplasias Renais/patologia , Masculino , Pessoa de Meia-Idade , Inibidores de Proteínas Quinases/administração & dosagem , Quinazolinas/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Proteínas Recombinantes , Estados Unidos , United States Food and Drug Administration , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidoresRESUMO
BACKGROUND: Characterisation of human papilloma virus (HPV) infection in anal squamous cell carcinoma (ASCC) may have dual importance: first, aetiological; second, prognostic, informing outcome after chemo-radiotherapy (CRT). We undertook HPV genotyping, and allelic characterisations, to evaluate the aetiological role of HPV while simultaneously evaluating the impact of HPV genotyping on relapse-free (RFS) and overall survival (OS). METHOD: Dual-primer HPV genotyping (subtypes 6, 11, 16, 18, 31, 33, 45, 52, 58) and DNA sequencing of HPV 16 positive tumours were analysed in 151 consecutively referred ASCCs, previously characterised by immunohistochemistry for p16 expression. In 110 patients treated with CRT, factors influencing RFS and OS were evaluated using univariate and multivariate models. RESULTS: HPV positivity was observed in 95%. HPV 16 accounted for 89%; of these, 64% harboured the T350G E6 variant. HPV 16 positivity was significantly correlated with improved 5-year RFS (62% versus 40%; p = 0.027) and OS (59% versus 38%; p = 0.019). p16 expression was also significantly correlated with improved 5-year RFS (positive versus negative: 65% versus 16%; p < 0.0001) and OS (63% versus 13%; p < 0.0001). In multivariable models that included HPV 16 status, p16 status, sex, and age, p16 expression remained an independent prognostic factor for RFS (p < 0.0001) and OS (p = 0.002). CONCLUSION: In ASCC, near-universal HPV detection rates were demonstrated, higher than generally reported in the literature, and supporting the development of multivalent HPV vaccinations for prevention. By contrast, p16 negatively, but not HPV 16 genotype, is an independent adverse prognosticator after chemo-radiotherapy in patients with ASCC.
Assuntos
Neoplasias do Ânus/prevenção & controle , Neoplasias do Ânus/virologia , Carcinoma de Células Escamosas/prevenção & controle , Carcinoma de Células Escamosas/virologia , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Ânus/patologia , Carcinoma de Células Escamosas/patologia , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Papillomaviridae/genética , Papillomaviridae/imunologia , Infecções por Papillomavirus/virologia , Prognóstico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
There is some evidence that repetitive transcranial magnetic stimulation (rTMS) can alleviate the experience of chronic pain. The mechanisms by which rTMS may induce pain relief, however, are unknown. The present study examined whether a session of rTMS would produce sensory threshold changes in healthy individuals. Detection and pain thresholds for cold sensations were compared following low frequency (1 Hz) (Experiment 1) and high frequency (20 Hz) (Experiment 2) repetitive TMS. While cold detection threshold was significantly lowered by both rTMS rates, only high frequency rTMS produced a significant change in cold pain threshold. In contrast, sham rTMS did not alter thresholds for cold stimuli. These findings provide evidence that sensory thresholds can be influenced by repetitive transcranial magnetic stimulation.
Assuntos
Temperatura Baixa , Estimulação Elétrica , Córtex Motor/efeitos da radiação , Limiar Sensorial/efeitos da radiação , Estimulação Magnética Transcraniana , Adulto , Análise de Variância , Relação Dose-Resposta à Radiação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Córtex Motor/fisiologia , Medição da Dor/métodosRESUMO
The current study examined the measurement and structural invariance of the Depression Anxiety Stress Scales-21 (DASS-21) across ratings provided by men (N = 227) and women (N = 460). Multiple-group confirmatory factor analysis (CFA) supported full metric invariance and intercepts invariance for 20 of the 21 items. Invariance for all item intercepts was supported by multiple indicators multiple causes (MIMIC) procedure that controlled for the effects of age. Multiple-group CFA supported invariance for all factor variances and covariances. This procedure and the MIMIC analyses found equivalency for all latent mean scores. These findings indicate good support for measurement and structural invariance of the DASS-21 rating across men and women. The psychometric and practical implications of the findings are discussed.
Assuntos
Ansiedade/psicologia , Depressão/psicologia , Testes Psicológicos , Estresse Fisiológico , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores SexuaisAssuntos
Envelhecimento/psicologia , Desempenho Psicomotor , Idoso , Criança , Pré-Escolar , Humanos , LactenteRESUMO
BACKGROUND AND PURPOSE: Squamous cell carcinomas of the anal canal are associated with infection with Human Papilloma Viruses (HPVs). Chemo-radiotherapy (CRT) gives 70% 3-year relapse-free survival. Improved predictive markers and therapeutic options are required. METHODS: Tumours from 153 patients treated with radical chemo-radiotherapy (50.4 Gy in 28# with concurrent Mitomycin and 5-Fluorouracil between 2004 and 2009) were retrieved and immunohistochemistry performed for p16(INK4A), p53 and EGFR and correlated with outcome. Primary and relapsed samples were analysed for mutations in KRAS. RESULTS: 137/153 (89.5%) stained moderately or strongly for p16(INK4A). p16(INK4A) correlated strongly with outcome. 37/137 patients demonstrating moderate/strong p16(INK4A) expression relapsed (27.0%), as opposed to 10/16 (62.5%) with absent/weak staining (log rank test p<0.001). p16 and p53 expression were inversely correlated. p16(INK4A) negative tumours were more frequent in men. p16(INK4A) negative patients had significantly worse overall survival (p<0.001). No mutations in KRAS were identified in primary tumours or relapses following treatment. CONCLUSIONS: p16(INK4A) is strongly associated with relapse in SCC of the anus and identifies patients with very poor rates of relapse-free and overall survival. Primary and recurrent anal cancer expresses wild type KRAS, unaffected by treatment, supporting trials targeting EGFR in poor risk/recurrent anal cancer.
Assuntos
Neoplasias do Ânus/terapia , Carcinoma de Células Escamosas/terapia , Quimiorradioterapia , Receptores ErbB/análise , Mutação , Proteínas de Neoplasias/análise , Proteínas Proto-Oncogênicas/genética , Proteína Supressora de Tumor p53/análise , Proteínas ras/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Ânus/química , Neoplasias do Ânus/mortalidade , Neoplasias do Ânus/patologia , Carcinoma de Células Escamosas/química , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Inibidor p16 de Quinase Dependente de Ciclina , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Proteínas Proto-Oncogênicas p21(ras)RESUMO
Sarcomatoid carcinoma is a rare tumor with a poor prognosis, otherwise known as carcinosarcoma. Gastrointestinal origin is very rare and only a limited number of anal carcinosarcomas have been reported in the literature. The management of this rare cancer type is controversial. The aim of this case report was to confirm that by combining treatment modalities we can achieve long disease free intervals. Concomitant chemoradiotherapy led to a good partial response and this was followed by a consolidation surgical endo-anal excision.
RESUMO
Primary motor cortex (M1) plays a role in motor learning, although the exact nature of that involvement remains unclear. The present study examined the relationship between motor learning and cortical plasticity by manipulating augmented feedback during motor training. Two groups of 10 participants performed a wrist flexion-extension waveform-tracking task with either concurrent and terminal augmented feedback after every trial (100% FB) or only terminal feedback after every alternate trial (50% FB). Single- and paired-pulse transcranial magnetic stimulation (TMS) was used to assess cortical excitability short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF) before, after, and 24 h following (retention) motor training. The 50% FB group performed better at retention than the 100% FB group, indicative of enhanced learning due to reduced FB scheduling. Cortical excitability did not change during acquisition for either group, however, the 50% FB group had elevated M1 excitability at retention, suggesting M1 involvement in the consolidation of learning. Reduced SICI following practice suggests a reduction of intracortical inhibition during motor skill acquisition. ICF was unchanged. It is concluded that the nature of M1 modulation associated with the acquisition and retention of a novel motor skill appears to vary with the nature and complexity of task requirements.
Assuntos
Aprendizagem/fisiologia , Atividade Motora/fisiologia , Córtex Motor/fisiologia , Adolescente , Adulto , Retroalimentação , Feminino , Lateralidade Funcional , Humanos , Masculino , Plasticidade Neuronal , Filtro Sensorial/fisiologia , Estudantes , Punho/fisiologia , Adulto JovemRESUMO
Research has shown that transcranial magnetic stimulation (TMS) results in a transient reduction in the experience of chronic pain. The present research aimed to investigate whether a single session of high frequency TMS is able to change the sensory thresholds of individuals suffering from chronic pain. Detection and pain thresholds for cold and heat sensations were measured before and after 20Hz repetitive TMS (rTMS) administered over the motor cortex. A significant decrease in temperature for cold detection and pain thresholds and a significant increase in temperature for heat pain thresholds were evident following a single session of rTMS. In contrast, no change in detection and pain thresholds was obtained following sham rTMS. The finding that rTMS can have a direct effect on sensory thresholds in individuals suffering from chronic pain has implications for the therapeutic use of rTMS in the relief of chronic pain.
Assuntos
Dor nas Costas/terapia , Córtex Motor/fisiopatologia , Limiar da Dor , Limiar Sensorial , Estimulação Magnética Transcraniana , Adulto , Idoso , Analgésicos/uso terapêutico , Lesões nas Costas/complicações , Dor nas Costas/tratamento farmacológico , Dor nas Costas/etiologia , Dor nas Costas/fisiopatologia , Doença Crônica , Temperatura Baixa/efeitos adversos , Terapia Combinada , Feminino , Temperatura Alta/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Tato , Resultado do TratamentoRESUMO
There are a number of structural constraints on the coordination of the two hands. Understanding bimanual coordination involves not only identification of these constraints but also how they can be overcome or modulated. The performance of polyrhythms has been used to examine these issues. In this article the constraints on coordination are outlined and research on the acquisition of polyrhythms is reviewed. It is suggested that the constraints on the production of multifrequency ratios are overcome by integrating the timing of the two hands. Oscillator models of coordination are then considered and a two-process model of motor timing is suggested.
Assuntos
Mãos/fisiologia , Aprendizagem , Movimento/fisiologia , Desempenho Psicomotor/fisiologia , Humanos , Fatores de TempoRESUMO
The spatial and temporal coupling between the hands is known to be very robust during movements which use homologous muscles (in-phase or symmetric movements). In contrast, movements using nonhomologous muscles (antiphase or asymmetric movements) are less stable and exhibit a tendency to undergo a phase transition to in-phase movements as movement frequency increases. The instability during antiphase movements has been modeled in terms of signal interference mediated by the ipsilateral corticospinal pathways. In this study we report that participants in whom distal ipsilateral motor-evoked potentials could be elicited with transcranial magnetic stimulation (TMS), exhibited higher variability during a bimanual circling task than participants whose ipsilateral pathways could not be transcranially activated. These results suggest that ipsilateral control of the limb affects the level of bimanual coupling, and may contribute to uncoupling phenomena observed during asymmetric coordination.
Assuntos
Vias Eferentes/fisiologia , Lateralidade Funcional/fisiologia , Movimento/fisiologia , Desempenho Psicomotor/fisiologia , Adulto , Campos Eletromagnéticos , Eletromiografia , Potencial Evocado Motor/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Córtex Motor/fisiologia , Percepção Espacial/fisiologiaRESUMO
In 6 patients with Parkinson's disease (PD) and 6 age-matched controls, transcranial magnetic stimulation was applied at 56 regions over the motor cortex and premotor cortex of each hemisphere, with the first dorsal interosseous (FDI) muscle of both hands activated at 15% maximum voluntary contraction during stimulation. For each site, motor evoked potential (MEP) landmarks were recovered, including MEP amplitude, MEP onset latency, and silent period duration. Scaled MEP amplitudes were used to construct individual cortical maps of the FDI muscles. The maps revealed an anterior displacement of the muscle representation in PD patients. This anterior shift over motor cortical areas may reflect increased contributions of corticocortical connections between motor cortex and premotor cortical areas, possibly enhanced by the visual feedback aspect of the task. These alterations may reflect adaptations to the impairments in striatocortical circuits in PD.